|
BioScreening - organic compounds for screening
News: Cancer ResearchKINAXO’s Cellular Target Profiling® reveals mTOR as a new target of Celebrex - Martinsried, Germany, April 29, 2009 / b3c newswire / - Kinaxo Biotechnologies GmbH has successfully applied its Cellular Target Profiling® technology to identify the protein kinase mTOR as a new cellular target of celecoxib (Celebrex®, Pfizer). Celecoxib is a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis [...]
Molecular Fingerprints Point The Way To Earlier Cancer Diagnosis And More Targeted Treatment - ScienceDaily (Mar. 27, 2009) — Metabolites are molecular fingerprints of what your cells are up to and Dr. Arun Sreekumar wants to know the impression made by cancer.
You’ve likely heard about metabolites; your physician probably screens for some known ones such as triglycerides or cholesterol at your annual physical. Scientists suspect we have about 3,000 [...]
Fruit flies soar as lab model, drug screen for the deadliest of human brain cancers - LA Jolla, CA—Fruit flies and humans share most of their genes, including 70 percent of all known human disease genes. Taking advantage of this remarkable evolutionary conservation, researchers at the Salk Institute for Biological Studies transformed the fruit fly into a laboratory model for an innovative study of gliomas, the most common malignant brain tumors.
“Gliomas [...]
CytRx Unveils Clinical Development Plan for Pipeline Assets - Names World-Renowned Cancer Drug Expert Dr. Joseph Rubinfeld as Chief Scientific Advisor
LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug [...]
The German Cancer Research Center Investigates the Role of miRNAs in Carcinogenesis Using febit’s Geniom RT Analyzer - LEXINGTON, Mass. (USA), and HEIDELBERG, Germany, Oct. 20, 2008 - The German Cancer
Research Center, also known as DKFZ, in Heidelberg (Germany) chose febit´s newly
introduced Geniom® RT Analyzer to investigate the association of microRNAs (miRNAs)
and cancer.
miRNAs are small pieces of RNA with a maximum length of 23 nucleotides, which have
become an important focus of life-science research [...]
deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer - Detection may be used to complement and target screening for the disease; findings will be integrated into the deCODEme(TM) personal genome scan.
Last update: 1:30 p.m. EDT Sept. 14, 2008
REYKJAVIK, Iceland, Sept 14, 2008
DCGN and colleagues at Radboud University Medical Center in the Netherlands today report the discovery of two common single-letter variants in the human [...]
Colon Cancer Oncogene Discovered - SUNDAY, Sept. 14 (HealthDay News) — Researchers have identified a new genetic player in the development of colon cancer.
The findings implicate CDK8, a protein that regulates gene expression in the proliferation of colorectal cancer, the researchers found.
Should the results be validated, they could lead to new therapeutic approaches for colon cancer, as well as new [...]
TOCRIS SIGNS EXCLUSIVE DEAL TO SUPPLY GEFITINIB - September 4th, 2008 - Tocris Bioscience announced today the signing of an exclusive deal with AstraZeneca to supply Gefitinib (also known as Iressa and ZD1839) to preclinical researchers working on the mechanisms underlying cancer development. For the first time, scientists will be able to buy authentic, fully licensed, non-formulated Gefitinib as an off-the shelf product [...]
New drug slows down cancer - WA researchers have taken the first step towards developing new anti-cancer medications that could activate a gene shown to block the growth of cancerous cells.
Led by Western Australian Institute for Medical Research (WAIMR) Director Professor Peter Klinken, the scientists have screened a large collection of drug-like molecules and recently identified a number of compounds which [...]
AstraZeneca, Singapore institutions sign innovative new partnership to develop anti-cancer compounds - Healthcare company AstraZeneca Plc (AZN: News, Chart, Quote ,AZN.L: News, Chart, Quote ) said Friday that it signed an innovative new partnership with the National Cancer Centre Singapore, or NCCS, and the National University Hospital, or NUH, for development of anti-cancer compounds. The [...]
Invitrogen Scientists Link microRNA Sequences to Cancer Using RNA Samples from BioServe - Carlsbad, Calif., and Beltsville, Md., May 7, 2008 – In research demonstrating that RNA previously thought to have no biological relevance may be of use for therapeutic and diagnostic targets, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, and BioServe, the leading provider of clinically annotated tissue samples [...]
Validated biomarkers will drive personalized medicine - Biomarkers will be accepted as predicted tools, but their clinical usefulness needs to be understood
first, according to personalized medicine expert.
Coordinating personalized medicine on an international level, Dr Edward Abrahams, Executive
Director of the Personalized Medicine Coalition believes that biomarkers will eventually impact all
disease areas.
“When they were validated, and when it can be understood how clinically useful [...]
Norwich company joins cancer fight - A new company based on the Norwich Research Park has joined the fight against MRSA and cancer.
Researchers at the John Innes Centre near Norwich have launched a new company, Inspiralis, based around their expertise in ‘DNA topoisomerases’.
These are a group of enzymes that help DNA molecules to unravel and wind up properly and not to [...]
DNA with a twist: New company to search for cancer drugs and antibiotics - A new company has joined the fight against MRSA and cancer. Researchers at the John Innes Centre (Norwich) have launched a new company, Inspiralis Ltd, based around their expertise in DNA topoisomerases – a group of enzymes that help DNA molecules to unravel and wind up properly and not to become tangled during replication.
“DNA becomes [...]
New drug target leaves lung cancer cells alone, lonely and dying - It seems even tumour cells can get lonely; scientists have discovered that by cutting off a key gene, lung cancer tumour cells are left ‘homeless’ and they can’t survive on their own.
The gene in question is called 14-3-3zeta and it can now be considered a potential target for selective anticancer drugs, according to Professor Haian [...]
Michael J. Fox Foundation Awards $4.4 Million for Development of New Class of Parkinson’s Therapy - NEW YORK, Dec. 18 /PRNewswire-USNewswire/ — The Michael J. Fox Foundation has awarded $4.4 million to jump-start the development of a new class of symptomatic Parkinson’s disease drugs targeting glutamate receptor mGluR4. The funding was awarded to a multidisciplinary team of researchers led by Jeffrey Conn, PhD, of Vanderbilt University under the Foundation’s LEAPS (Linked [...]
Profiling of Tumor Tissue Slices is Awarded Prize - Novel drug screening tool based on the Bionas® 2500 analyzing system wins silver medal in European business plan contest
Rostock, Germany, November 26, 2007 / b3c newswire / - Bionas GmbH, a specialist for in vitro profiling the metabolic activity of cells, announced that Prof. Pedro Mestres of the Saarland University (Homburg/Saar, Germany) has been awarded [...]
Gossypol Biological Properties - Gossypol:
is a polyphenolic aldehyde that permeates cells and acts as an inhibitor for several dehydrogenase enzymes.
is antimalarial being the selective inhibitor of Plasmodium falciparum (pfLDH over hLDHs), an essential enzyme for energy generation within malarial parasite.
posesses proapoptotic properties, probably due to the regulation of the Bax and Bcl2.
reversibly inhibits Calcineurin and binds to calmodulin.
inhibits replication [...]
Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog - NEWARK, Del., Oct. 2 /PRNewswire-FirstCall/ — Strategic Diagnostics Inc. — today announced the launch of a new internet based catalog of antibody reagents in support of oncology-based research and discovery. These high-quality reagents have all been manufactured utilizing SDI’s proprietary Genomic Antibody Technology(TM) and will carry the SEQer(TM) brand. The catalog is available at http://antibodies.sdix.com [...]
BioServe and Phenomenome Discoveries Develop Novel Diagnostic Test for Colorectal Cancer - Laurel, MD and Saskatoon, SK, Canada, August 6, 2007 – BioServe and Phenomenome Discoveries Inc. (“PDI”) today announced that they have developed a novel serum-based diagnostic test for the identification of colorectal cancer (CRC), and pre-cancerous states conducive to the development of CRC. Colorectal cancer comprises a tenth of the global [...]
Sponsored Links
|
|
